am I the only one who found hepatic fat harder than the injections
Right, the glucagon question again, but with numbers this time.
I have 7 data points over 8 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign.
The thing I would flag for anyone new: the effect I am describing showed up at week 43, not week 92. People give up long before the interesting part.
Interested in whether this matches other people's logs or whether I am an outlier.
best — the order this archive was captured in
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.
The thing nobody prepared me for was the quiet. Not the appetite, the quiet. The constant negotiation in my head about food just stopped.
Stalled for 9 weeks, changed nothing, and it started moving again on week 87.
Retitled to remove editorialising. Put the evidence in the body.
Australia here. Waited 3 months on a list, gave up, went private, and the total cost was roughly what I expected.
Hepatic fat or MASH or what?
the safety profile is not just tirzepatide amplified
the UK here. Waited 19 months on a list, gave up, went private, and the total cost was roughly what I expected.
This is correct. Do not generalise from tirzepatide.
Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.
Strongly agree. The safety story is separate.
- 1Retitled to remove editorialising. Put the evidence in the body.6 comments in this branch · started by u/incretin_ivy
- 2Inter-lab variance on this kind of assay is routinely 1–2 points. Different…4 comments in this branch · started by u/kaia_kuusela